Preconditioning Strategies for Improving the Survival Rate and Paracrine Ability of Mesenchymal Stem Cells in Acute Kidney Injury

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2018 Nov 29

PMID 30484934

Citations 37

Authors

Lingfei Zhao

Chenxia Hu

Ping Zhang

Hua Jiang

Jianghua Chen

Affiliations

Soon will be listed here.

Abstract

Acute kidney injury (AKI) is a common, severe emergency case in clinics, with high incidence, significant mortality and increased costs. Despite development in the understanding of its pathophysiology, the therapeutic choices are still confined to dialysis and renal transplantation. Considering their antiapoptotic, immunomodulatory, antioxidative and pro-angiogenic effects, mesenchymal stem cells (MSCs) may be a promising candidate for AKI management. Based on these findings, some clinical trials have been performed, but the results are contradictory (NCT00733876, NCT01602328). The low engraftment, poor survival rate, impaired paracrine ability and delayed administration of MSCs are the four main reasons for the limited clinical efficacy. Investigators have developed a series of preconditioning strategies to improve MSC survival rates and paracrine ability. In this review, by summarizing these encouraging studies, we intend to provide a comprehensive understanding of various preconditioning strategies on AKI therapy and improve the prognosis of AKI patients by regenerative medicine.

Citing Articles

Cellular Stem Cell Therapy for Treating Traumatic Brain Injury: Strategies for Enhancement of Therapeutic Efficacy.

Khazaal A, Ismaeel H, Cheah P, Nordin N Mol Neurobiol. 2025; .

PMID: 40000574 DOI: 10.1007/s12035-025-04778-9.

Standardization to Characterize the Complexity of Vessel Network Using the Aortic Ring Model.

Wolint P, Hofmann S, von Atzigen J, Boni R, Miescher I, Giovanoli P Int J Mol Sci. 2025; 26(1.

PMID: 39796147 PMC: 11719671. DOI: 10.3390/ijms26010291.

Cell therapy in kidney diseases: advancing treatments for renal regeneration.

Salybekov A, Kinzhebay A, Kobayashi S Front Cell Dev Biol. 2024; 12:1505601.

PMID: 39723242 PMC: 11669058. DOI: 10.3389/fcell.2024.1505601.

The application of extracorporeal shock wave therapy on stem cells therapy to treat various diseases.

Kou D, Chen Q, Wang Y, Xu G, Lei M, Tang X Stem Cell Res Ther. 2024; 15(1):271.

PMID: 39183302 PMC: 11346138. DOI: 10.1186/s13287-024-03888-w.

Characterization of MSCs expressing islet neogenesis associated protein (INGAP): INGAP secretion and cell survival and .

Petropavlovskaia M, Assouline-Thomas B, Cuerquis J, Zhao J, Violette-Deslauriers S, Nano E Heliyon. 2024; 10(15):e35372.

PMID: 39170459 PMC: 11336584. DOI: 10.1016/j.heliyon.2024.e35372.

References

Morigi M, Benigni A . Mesenchymal stem cells and kidney repair. Nephrol Dial Transplant. 2012; 28(4):788-93. DOI: 10.1093/ndt/gfs556. View

Jung M, Sola A, Hughes J, Kluth D, Vinuesa E, Vinas J . Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int. 2012; 81(10):969-982. DOI: 10.1038/ki.2011.446. View

Li J, Zhang N, Wang J . Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest. 2008; 31(2):103-10. DOI: 10.1007/BF03345575. View

Feng G, Zhang J, Li Y, Nie Y, Zhu D, Wang R . IGF-1 C Domain-Modified Hydrogel Enhances Cell Therapy for AKI. J Am Soc Nephrol. 2016; 27(8):2357-69. PMC: 4978042. DOI: 10.1681/ASN.2015050578. View

Tsubokawa T, Yagi K, Nakanishi C, Zuka M, Nohara A, Ino H . Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am J Physiol Heart Circ Physiol. 2010; 298(5):H1320-9. DOI: 10.1152/ajpheart.01330.2008. View

Hasty K, Cho H . Stem Cell Considerations for the Clinician. Phys Med Rehabil Clin N Am. 2016; 27(4):855-870. PMC: 5119921. DOI: 10.1016/j.pmr.2016.06.004. View

Gnecchi M, He H, Liang O, Melo L, Morello F, Mu H . Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11(4):367-8. DOI: 10.1038/nm0405-367. View

Robey T, Saiget M, Reinecke H, Murry C . Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol. 2008; 45(4):567-81. PMC: 2587485. DOI: 10.1016/j.yjmcc.2008.03.009. View

He A, Jiang Y, Gui C, Sun Y, Li J, Wang J . The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol. 2009; 25(6):353-8. PMC: 2722478. DOI: 10.1016/s0828-282x(09)70094-7. View

10.

Crisostomo P, Wang Y, Markel T, Wang M, Lahm T, Meldrum D . Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol. 2008; 294(3):C675-82. DOI: 10.1152/ajpcell.00437.2007. View

11.

Zhang Y, Yu Z, Jiang D, Liang X, Liao S, Zhang Z . iPSC-MSCs with High Intrinsic MIRO1 and Sensitivity to TNF-α Yield Efficacious Mitochondrial Transfer to Rescue Anthracycline-Induced Cardiomyopathy. Stem Cell Reports. 2016; 7(4):749-763. PMC: 5063626. DOI: 10.1016/j.stemcr.2016.08.009. View

12.

Liangos O, Wald R, Obell J, Price L, Pereira B, Jaber B . Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol. 2007; 1(1):43-51. DOI: 10.2215/CJN.00220605. View

13.

Joswig A, Mitchell A, Cummings K, Levine G, Gregory C, Smith 3rd R . Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther. 2017; 8(1):42. PMC: 5329965. DOI: 10.1186/s13287-017-0503-8. View

14.

Pleniceanu O, Harari-Steinberg O, Dekel B . Concise review: Kidney stem/progenitor cells: differentiate, sort out, or reprogram?. Stem Cells. 2010; 28(9):1649-60. PMC: 2996087. DOI: 10.1002/stem.486. View

15.

Chang W, Song B, Moon J, Cha M, Ham O, Lee S . Anti-death strategies against oxidative stress in grafted mesenchymal stem cells. Histol Histopathol. 2013; 28(12):1529-36. DOI: 10.14670/HH-28.1529. View

16.

Hourd P, Ginty P, Chandra A, Williams D . Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy. 2014; 16(8):1033-47. DOI: 10.1016/j.jcyt.2014.03.005. View

17.

Abdi R, Fiorina P, Adra C, Atkinson M, Sayegh M . Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008; 57(7):1759-67. PMC: 2453631. DOI: 10.2337/db08-0180. View

18.

Gao J, Liu R, Wu J, Liu Z, Li J, Zhou J . The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials. 2012; 33(14):3673-81. DOI: 10.1016/j.biomaterials.2012.01.061. View

19.

Park W, Ahn S, Sung S, Ahn J, Chang Y . Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders. Pediatr Res. 2017; 83(1-2):214-222. DOI: 10.1038/pr.2017.249. View

20.

Overath J, Gauer S, Obermuller N, Schubert R, Schafer R, Geiger H . Short-term preconditioning enhances the therapeutic potential of adipose-derived stromal/stem cell-conditioned medium in cisplatin-induced acute kidney injury. Exp Cell Res. 2016; 342(2):175-83. DOI: 10.1016/j.yexcr.2016.03.002. View